Enhanced levels of the NGAL/MMP9 complex, but not of MMP-9 and lipocalin-2, have been related to worse clinical outcome in cancer patients and significantly associated with the classifications of Lauren and WHO, suggesting that NGAL/MMP9 complex could be considered as a novel prognostic factor for gastric cancer [13]. This evidence concerns the gene MMP9 and cancer.